Literature DB >> 12032905

Attributable mortality of Stenotrophomonas maltophilia bacteremia.

Esin Senol1, Jeffrey DesJardin, Paul C Stark, Laurie Barefoot, David R Snydman.   

Abstract

A systematic evaluation of the attributable mortality of Stenotrophomonas maltophilia bacteremia was undertaken in a matched, retrospective, case-control study. We determined the attributable mortality rate (26.7%) and mortality risk ratio (an 8-fold increase) of S. maltophilia bacteremia. The attributable mortality rate for S. maltophilia bacteremia is similar to the attributable mortality rate for other nosocomial bloodstream infections.

Entities:  

Mesh：

Year:  2002        PMID： 12032905     DOI： 10.1086/340707

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  38 in total

1.  Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia.

Authors:  Gokhan Metan; Omrum Uzun
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004.

Authors:  G Aisenberg; K V Rolston; B F Dickey; D P Kontoyiannis; I I Raad; A Safdar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 3.267

3.  Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?

Authors:  Sun Young Cho; Cheol-In Kang; Jungok Kim; Young Eun Ha; Doo Ryeon Chung; Nam Yong Lee; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

4.  Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients.

Authors:  Hayati Demiraslan; Mustafa Sevim; Çiğdem Pala; Süleyman Durmaz; Veli Berk; Leylagül Kaynar; Gökhan Metan
Journal:  Int J Hematol       Date:  2013-02-22       Impact factor: 2.490

5.  Changing trends in etiology of bacteremia in patients with cancer.

Authors:  A Safdar; G H Rodriguez; M Balakrishnan; J J Tarrand; K V I Rolston
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

Review 6.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

7.  Stenotrophomonas maltophilia in the respiratory tract of medical intensive care unit patients.

Authors:  B Saugel; K Eschermann; R Hoffmann; A Hapfelmeier; C Schultheiss; V Phillip; F Eyer; K-L Laugwitz; R M Schmid; W Huber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-07       Impact factor: 3.267

Review 8.  Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline.

Authors:  Sara E Boyd; David M Livermore; David C Hooper; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

9.  Structure of aminodeoxychorismate synthase from Stenotrophomonas maltophilia.

Authors:  Asim K Bera; Vesna Atanasova; Anjali Dhanda; Jane E Ladner; James F Parsons
Journal:  Biochemistry       Date:  2012-12-11       Impact factor: 3.162

10.  High genetic diversity among Stenotrophomonas maltophilia strains despite their originating at a single hospital.

Authors:  Sylvia Valdezate; Ana Vindel; Pilar Martín-Dávila; Begoña Sánchez Del Saz; Fernando Baquero; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.